
Expanded Access to Telisotuzumab Vedotin
Non-Small Cell Lung Cancer (NSCLC)This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

SurVaxM Expanded Access Protocol
GlioblastomaData from clinical trials suggest that SurVaxM administered as a single agent, or in combination with standard glioblastoma chemotherapy treatment regimens to patients with recurrent or newly diagnosed glioblastoma, is generally well tolerated and may increase progression free survival and overall survival in some patients

Expanded Access to Tipifarnib
HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.

177Lu-PSMA-617 Managed Access Program for mCRPC Patients
Metastatic Castration-resistant Prostate Cancer (mCRPC)The purpose of this Cohort Treatment Plan is to allow access to 177Lu-PSMA-617 for eligible patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC). The patient's treating physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
LeukemiaLymphocytic10 moreThis is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

AMG 701 Expanded Access Program
Expanded access requests for AMG 701 may be considered for adult patients with relapsed and/or refractory multiple myeloma whose disease is in partial response or better after AMG 420 therapy. To request access, use Responsible Party contact information provided in this record.

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C...
Advanced CancerMetastatic Cancer1 moreThe objective of this EAP is to provide expanded access of adagrasib (MRTX849) to patients with previously treated advanced solid tumors harboring a KRAS G12C mutation.

Expanded Access for Fixed-Dose Combination of Nivolumab Plus Relatlimab
This is an expanded access designed to provide access to fixed-dose combination of nivolumab plus relatlimab for eligible participants.

Expanded Access for Anti-IL8
This is an expanded access designed to provide access to Anti-IL8 for eligible participants.

Flotetuzumab Expanded Access Program
Acute Myeloid LeukemiaAML2 moreThe purpose of the Expanded Access program is to provide flotetuzumab to patients with acute myeloid leukemia (AML) for whom potential benefit justifies potential treatment risks.